Ethinylestradiol/Chlormadinone Acetate
Tóm tắt
Acne vulgaris, hirsutism, seborrhea and female pattern hair loss (FPHL) are common disorders of the pilosebaceous unit (PSU). In some women with hyperandrogenemia, an excess of androgens at the PSU can lead to the development of these dermatological manifestations. These manifestations can cause many psychiatric and psychological implications, such as social fears and anxiety, and can adversely affect quality of life. High androgen levels at the PSU as a possible underlying cause of acne vulgaris, hirsutism, seborrhea and FPHL supports the rationale for using combined oral contraceptives for the management of these conditions in women. The purpose of this review is to describe these dermatological manifestations of the PSU and the management of these conditions through the use of the oral contraceptive ethinylestradiol/chlormadinone acetate (EE/CMA). EE/CMA 0.03/2mg is a combined monophasic contraceptive pill with anti-androgenic properties. It is approved in Europe for contraception and has been investigated in phase III trials for the treatment of acne. EE/CMA was better than placebo and similar to another low-dose oral contraceptive (ethinylestradiol/levonorgestrel) in improving symptoms of acne in two phase III randomized controlled trials in patients with mild to moderate papulopustular acne. In addition, in trials investigating the contraceptive efficacy of EE/CMA, limited data suggest that there were also improvements in hirsutism, FPHL and seborrhea in small subgroups of patients. EE/CMA has a good safety profile. The most commonly reported adverse events are breast tenderness/pain, headache/migraine and nausea. Evidence in the literature indicates that the use of EE/CMA for the treatment of dermatological disorders under the control of androgens may be a valid treatment option. Further investigation is warranted.
Tài liệu tham khảo
Wiegratz I, Kuhl H. Managing cutaneous manifestations of hyperandrogenic disorders: the role of oral contraceptives. Treat Endocrinol 2002; 1 (6): 372–86
Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev 2000 Aug; 21 (4): 363–92
Rivera R, Guerra A. Management of acne in women over 25 years of age. Actas Dermosifiliogr 2009 Jan-Feb; 100 (1): 33–7
Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007 Apr; 56 (4): 651–63
van Vloten WA, Sigurdsson V. Selecting an oral contraceptive agent for the treatment of acne in women. Am J Clin Dermatol 2004; 5 (6): 435–41
Homburg R, Lambalk CB. Polycystic ovary syndrome in adolescence — a therapeutic conundrum. Hum Reprod 2004 May; 19 (5): 1039–42
Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older [published erratum appears in J Am Acad Dermatol 2008 May; 58 (5): 874]. J Am Acad Dermatol 2008 Jan; 58 (1): 56–9
Hanna S, Sharma J, Klotz J. Acne vulgaris: more than skin deep [abstract]. Dermatol Online J 2003 Aug; 9 (3): 8
Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999 Apr; 140 (4): 672–6
Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol 1999 Feb; 140 (2): 273–82
Castello R, Tosi F, Perrone F, et al. Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil Steril 1996 Nov; 66 (5): 734–40
Alsantali A, Shapiro J. Management of hirsutism. Skin Therapy Lett 2009 Sep; 14 (7): 1–3
Sonino N, Fava GA, Mani E, et al. Quality of life of hirsute women. Postgrad Med J 1993 Mar; 69 (809): 186–9
Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001 Jan; 27 (1): 53–4
Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol 1999 Sep; 141 (3): 398–405
Rivera R, Guerra-Tapia A. Management of androgenetic alopecia in postmenopausal women. Actas Dermosifiliogr 2008 May; 99 (4): 257–61
Johnson BA, Nunley JR. Treatment of seborrheic dermatitis. Am Fam Physician 2000 May 1; 61 (9): 2703–10, 13-4
Elewski BE. Safe and effective treatment of seborrheic dermatitis. Cutis 2009 Jun; 83 (6): 333–8
Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician 2006 Jul 1; 74 (1): 125–30
Zouboulis CC, Xia L, Akamatsu H, et al. The human sebocyte culture model provides new insights into development and management of seborrhoea and acne. Dermatology 1998; 196 (1): 21–31
Sancho B, Guerra-Tapia A. Oral contraceptives in dermatology. Actas Dermosifiliogr 2009 Jul-Aug; 100 (6): 445–55
Givens JR, Andersen RN, Wiser WL, et al.Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive. J Clin Endocrinol Metab 1974 May; 38 (5): 727–35
Shaw JC. Acne: effect of hormones on pathogenesis and management. Am J Clin Dermatol 2002; 3 (8): 571–8
Worret I, Arp W, Zahradnik HP, et al. Acne resolution rates: results of a singleblind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001; 203 (1): 38–44
Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception 2003 Apr; 67 (4): 305–12
Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2mg/ethinylestradiol 0.03 mg (Belara). Clin Drug Investig 2002; 22 (4): 221–31
Curran MP, Wagstaff AJ. Ethinylestradiol/chlormadinone acetate. Drugs 2004; 64 (7): 751–60; discussion 61-2
Grünenthal GmbH. Belara®: highlight of the products properties (product monograph) [online]. Available from URL: (http://www.grunenthal.com/cms/cda/_common/inc/display_file.jsp?fileID=85500520) [Accessed 2010 Aug 3].
Plewig G, Cunliffe WJ, Binder N, et al. Efficacy of an oral contraceptive containing EE 0.03 mg andCMA2mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009 Jul; 80 (1): 25–33
Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 1999 Nov; 181 (5 Pt 1): 1263–9
Saunders DM, Marcus SL, Saxena BB, et al. Effect of daily administration of 0.5 mg. of chlormadinone acetate on plasma levels of follicle-stimulating hormone, luteinizing hormone, and progesterone during the menstrual cycle. Fertil Steril 1971 May; 22 (5): 332–44
Larsson-Cohn U, Johansson ED, Wide L, et al. Effects of continuous daily administration of 0.5mg of chlormadinone acetate on the plasma levels of progesterone and on the urinary excretion of luteinizing hormone and total oestrogens. Acta Endocrinol (Copenh) 1970 Apr; 63 (4): 705–16
Kreitmann B, Bugat R, Bayard F. Estrogen and progestin regulation of the progesterone receptor concentration in human endometrium. J Clin Endocrinol Metab 1979 Dec; 49 (6): 926–9
Zahradnik HP, Goldberg J, Andreas JO. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 1998 Feb; 57 (2): 103–9
Zahradnik HP. Belara — a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea. Eur J Contracept Reprod Health Care 2005; 10 Suppl. 1: 12–8
Lello S, Primavera G, Colonna L, et al. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol 2008 Dec; 24 (12): 718–23
Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) — an open-label, prospective, noncontrolled, office-based phase III study. Contraception 2008 May; 77 (5): 337–43
Anthuber S, Schramm GA, Heskamp ML. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Invest 2010; 30 (4): 211–20
Sabatini R, Orsini G, Cagiano R, et al. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception 2007 Nov; 76 (5): 342–7
Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception 2007 Aug; 76 (2): 84–90
Kerscher M, Reuther T, Bayrhammer J, et al. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: an open-label, single-centre, phase IV study. Clin Drug Investig 2008; 28 (11): 703–11